Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer.

Biomark Insights · 2024 · PMC10903227 · PMID 38426070

Europe PMC DOI

hedged sentence

0.2050

closest p · 4.1× alpha

0.2050

boldest claim

The sentences

did not reach statistical significanceP = .205not close (p > 0.1)

Association of methylated ctDNA and risk of recurrence The presence of methylated ctDNA at diagnosis (prior to any treatment) was higher in patients with a future recurrence (n = 22, 61%) compared to those without a recurrence (n = 71, 49%), however, this did not reach statistical significance ( P = .205).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.